1RC Stock Overview
Through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments in the United Kingdom. More details
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Creo Medical Group PLC Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£0.24 |
52 Week High | UK£0.50 |
52 Week Low | UK£0.14 |
Beta | 0.83 |
1 Month Change | 44.58% |
3 Month Change | -0.83% |
1 Year Change | -51.42% |
3 Year Change | -85.45% |
5 Year Change | -87.56% |
Change since IPO | -72.57% |
Recent News & Updates
Recent updates
Shareholder Returns
1RC | DE Medical Equipment | DE Market | |
---|---|---|---|
7D | 0.8% | -1.7% | -0.4% |
1Y | -51.4% | -6.8% | 7.9% |
Return vs Industry: 1RC underperformed the German Medical Equipment industry which returned -6.8% over the past year.
Return vs Market: 1RC underperformed the German Market which returned 7.9% over the past year.
Price Volatility
1RC volatility | |
---|---|
1RC Average Weekly Movement | 11.1% |
Medical Equipment Industry Average Movement | 6.4% |
Market Average Movement | 4.9% |
10% most volatile stocks in DE Market | 11.8% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 1RC's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 1RC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2003 | 278 | Craig Gulliford | www.creomedical.com |
Creo Medical Group PLC, through its subsidiaries, engages in the research, development, manufacture, and sale of medical devices and instruments in the United Kingdom. It is developing CROMA, an energy platform that combines bipolar radiofrequency for precise localized cutting and microwave energy for controlled coagulation, to provide physicians with controllable devices delivered through an endoscope. The company also offers Speedboat Inject, an energy multimodal instrument for endoscopy; MicroBlate Fine, a microwave needle ablation device; MicroBlate Flex, a microwave ablation device designed for soft tissue ablation; SlypSeal Flex, an electrosurgical haemostasis device; and SpydrBlade Flex, a bipolar RF and microwave scissor device that grasps, cuts and, coagulates highly perfused tissues.
Creo Medical Group PLC Fundamentals Summary
1RC fundamental statistics | |
---|---|
Market cap | €92.14m |
Earnings (TTM) | -€27.01m |
Revenue (TTM) | €36.54m |
2.5x
P/S Ratio-3.4x
P/E RatioIs 1RC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
1RC income statement (TTM) | |
---|---|
Revenue | UK£30.30m |
Cost of Revenue | UK£15.30m |
Gross Profit | UK£15.00m |
Other Expenses | UK£37.40m |
Earnings | -UK£22.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.056 |
Gross Margin | 49.50% |
Net Profit Margin | -73.93% |
Debt/Equity Ratio | 30.0% |
How did 1RC perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/01/05 15:04 |
End of Day Share Price | 2025/01/03 00:00 |
Earnings | 2024/06/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Creo Medical Group PLC is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Christopher Donnellan | Cavendish |
Christopher Donnellan | Cavendish Historical (Cenkos Securities) |
Jyoti Prakash | Edison Investment Research |